Focus: Medtronic is a global medical device company headquartered in Phillipsburg, NJ, with market-leading positions across cardiovascular, neurology, ophthalmology, musculoskeletal, and women's health therapeutic areas. The company operates at enterprise scale with 609 active job openings.
Profile data last refreshed 7h ago · AI intelligence enriched 3w ago
Hot — 3012 jobs added in 30d
Net +1467 (3012 new, 1545 removed). Aggressive expansion phase.
Medtronic is a stable, commercial-first enterprise player best suited for market-facing careers and those seeking established device development pathways; consider timing given recent Diabetes BU restructuring.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Post-LOE generic dye; multiple ANDA entries indicate mature, commoditized product with limited growth potential.
Help build intelligence for Medtronic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Medtronic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE generic dye; multiple ANDA entries indicate mature, commoditized product with limited growth potential.
Post-LOE generic dye; multiple ANDA entries indicate mature, commoditized product with limited growth potential.
Post-LOE generic dye; multiple ANDA entries indicate mature, commoditized product with limited growth potential.
Post-LOE generic dye; multiple ANDA entries indicate mature, commoditized product with limited growth potential.
NDA-originated branded product approaching loss of exclusivity; transition to generic competition imminent.
Post-LOE generic dye; multiple ANDA entries indicate mature, commoditized product with limited growth potential.
4 discontinued, 2 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent Diabetes BU restructuring signals vulnerability in legacy franchises even within a stable mega-cap, requiring caution for diabetes-focused roles.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo